VICTORION-2 PREVENT

A randomized double-blind, placebo controlled, multicenter trial, assessing the impact of Inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease

Stage: followup
Medicine: Inclisiran
Population: ASCVD
Phase: III
First Patient In: 25 February 2022
Last Patient In: 21 August 2023
Last Patient Last Visit: 15 March 2027

National Lead

prof. dr. J. W. Jukema

Cardioloog

Study Director

drs. H.P. Swart

Cardioloog

Office Contact

M.J. van Doorn

WCN